Hepatitis B vaccine by intradermal route in non responder patients: An update

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10383-10394

  Filippelli, Martina ^a   Lionetti, Elena ^a   Gennaro, Alessia ^a   Lanzafame, Angela ^a   Arrigo, Teresa ^b   Salpietro, Carmelo ^b   La Rosa, Mario ^a   Leonardi, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Hepatitis B virus; Intradermal route; Non responders; Update; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY; RECOMBINANT VACCINE;

ARTICLE; CELIAC DISEASE; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; DOWN SYNDROME; HEMODIALYSIS; HEPATITIS B; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MENTAL DEFICIENCY; NONHUMAN; THALASSEMIA; TREATMENT RESPONSE; VACCINATION; BLOOD; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; TREATMENT FAILURE; VIROLOGY;

BIOLOGICAL MARKERS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; TREATMENT FAILURE; VACCINATION; VACCINES, SYNTHETIC;

EID: 84920623099     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10383     Document Type: Article

References (148)

1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125 [PMID: 16754644 DOI: 10.1093/epirev/mxj009]
2. Sylvan S. [WHO spearheads global initiative to eradicate hepatitis B]. Lakartidningen 2000; 97: 3738-3740 [PMID: 11016226]
3. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273 [PMID: 18848855 DOI: 10.1016/j.vaccine.2008.09.056]
4. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, Wang SS, Li YP, Zhang KL. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17: 2661-2666 [PMID: 10418916 DOI: 10.1016/S0264-410X(99)00031-6]
5. Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, Wiesinger K, Kollaritsch H. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19: 2055-2060 [PMID: 11228377 DOI: 10.1016/S0264-410X(00)00410-2]
6. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-1339 [PMID: 16249217 DOI: 10.1093/ije/dyi206]
7. Arguedas MR, McGuire BM, Fallon MB. Implementation of vaccination in patients with cirrhosis. Dig Dis Sci 2002; 47: 384-387 [PMID: 11855555 DOI: 10.1023/A:1013734525348]
8. Poland GA. Evaluating existing recommendations for hepatitis A and B vaccination. Am J Med 2005; 118 Suppl 10A: 16S-20S [PMID: 16271536 DOI: 10.1016/j.amjmed.2005.07.029]
9. Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, Halm U, Mössner J, Berr F. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31: 230-234 [PMID: 10613751 DOI: 10.1002/hep.510310134]
10. Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med 2005; 118 Suppl 10A: 21S-27S [PMID: 16271537 DOI: 10.1016/j.amjmed.2005.07.013]
11. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Infect Dis Clin North Am 2006; 20: 27-45 [PMID: 16527647 DOI: 10.1016/j.idc.2006.01.004]
12. Park SD, Markowitz J, Pettei M, Weinstein T, Sison CP, Swiss SR, Levine J. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr 2007; 44: 431-435 [PMID: 17414139 DOI: 10.1097/MPG.0b013e3180320654]
13. Chen J, Liang Z, Lu F, Fang X, Liu S, Zeng Y, Zhu F, Chen X, Shen T, Li J, Zhuang H. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with nonresponse to hepatitis B vaccine. Vaccine 2011; 29: 706-711 [PMID: 21111021 DOI: 10.1016/j.vaccine.2010.11.023]
14. Hutin YJ, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003; 327: 1075 [PMID: 14604927 DOI: 10.1136/bmj.327.7423.1075]
15. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994; 15: 269-274 [PMID: 8068173 DOI: 10.1016 /0167-5699(94)90006-X]
16. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-222 [PMID: 15039758 DOI: 10.1038/nri1310]
17. Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 1993; 92: 2587-2596 [PMID: 8254016 DOI: 10.1172/JCI116873]
18. Spellberg B. The cutaneous citadel: a holistic view of skin and immunity. Life Sci 2000; 67: 477-502 [PMID: 10993114 DOI: 10.1016/S0024-3205(00)00653-6]
19. Flacher V, Bouschbacher M, Verronèse E, Massacrier C, Sisirak V, Berthier-Vergnes O, de Saint-Vis B, Caux C, Dezutter-Dambuyant C, Lebecque S, Valladeau J. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 2006; 177: 7959-7967 [PMID: 17114468]
20. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7: 1201-1214 [PMID: 18844594 DOI: 10.1586/14760584.7.8.1201]
21. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008; 26: 3197-3208 [PMID: 18486285 DOI: 10.1016/j.vaccine.2008.03.095]
22. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, Caux C, Aït-Yahia S, Vicari A, Kaiserlian D, Dubois B. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006; 24: 191-201 [PMID: 16473831]
23. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, Lew AM, Shortman K, Heath WR, Carbone FR. Migratory dendritic cells transfer antigen to a lymph noderesident dendritic cell population for efficient CTL priming. Immunity 2006; 25: 153-162 [PMID: 16860764]
24. Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, Wasi C. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000; 78: 693-698 [PMID: 10859864]
25. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol 2009; 16: 1709-1719 [PMID: 19793898 DOI: 10.1128/CVI.00290-09]
26. Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia ™ licensed micro injection system. Hum Vaccin Immunother 2012; 8: 67-75 [PMID: 22293531]
27. Comparative trial of live attenuated measles vaccine in Hong Kong by intramuscular and intradermal injection. Bull World Health Organ 1967; 36: 375-384 [PMID: 5299670]
28. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 1997; 25: 323-338 [PMID: 9325001 DOI: 10.1006/biol.1997.0103]
29. McBean AM, Agle AN, Compaore P, Foster SO, McCormack WM. Comparison of intradermal and subcutaneous routes of cholera vaccine administration. Lancet 1972; 1: 527-529 [PMID: 4110029 DOI: 10.1016/S0140-6736(72)90187]
30. Nicholson KG, Prestage H, Cole PJ, Turner GS, Bauer SP. Multisite intradermal antirabies vaccination. Immune responses in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine. Lancet 1981; 2: 915-918 [PMID: 6117693]
31. Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, Viravan C, Sinhaseni A, Chiewbambroongkiat MK, Pouradier-Duteil X, Xueref C. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985; 1: 1059-1062 [PMID: 2860284 DOI: 10.1016/S0140-6736(85)92367-0]
32. Miller KD, Gibbs RD, Mulligan MM, Nutman TB, Francis DP. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 1983; 2: 1454-1456 [PMID: 6140546 DOI: 10.1016/S0140-6736(83)90800-0]
33. Clarke JA, Hollinger FB, Lewis E, Russell LA, Miller CH, Huntley A, Flynn NM. Intradermal inoculation with Heptavax-B. Immune response and histologic evaluation of injection sites. JAMA 1989; 262: 2567-2571 [PMID: 2530364 DOI: 10.1001/jama.262.18.2567]
34. Connolly JH, Dick GW. Antibody response following intradermal or oral administration of formalinised poliomyelitis. Lancet 1958; 2: 333-336 [PMID: 13576796 DOI: 10.1016/S0140-6736(58)90256-3]
35. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998; 16: 928-931 [PMID: 9682339 DOI: 10.1016/S0264-410X(97)00293-4]
36. Baxby D. Smallpox vaccination techniques; from knives and forks to needles and pins. Vaccine 2002; 20: 2140-2149 [PMID: 11972983 DOI: 10.1016/S0264-410X(02)00028-2]
37. Andersen P, Doherty TM. The success and failure of BCG -implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3: 656-662 [PMID: 16012514 DOI: 10.1038/nrmicro1211]
38. Flynn PM, Shenep JL, Mao L, Crawford R, Williams BF, Williams BG. Influence of needle gauge in Mantoux skin testing. Chest 1994; 106: 1463-1465 [PMID: 7956403 DOI: 10.1378/chest.106.5.1463]
39. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 2007; 82: 425-435 [PMID: 18064757]
40. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009; 27: 7304-7312 [PMID: 19849996 DOI: 10.1016/j.vaccine.2009.10.033]
41. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, Harvey NG. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25: 8833-8842 [PMID: 18023942]
42. Sangaré L, Manhart L, Zehrung D, Wang CC. Intradermal hepatitis B vaccination: a systematic review and metaanalysis. Vaccine 2009; 27: 1777-1786 [PMID: 19200451 DOI: 10.1016/j.vaccine.2009.01.043]
43. Sangfelt P, Uhnoo I, Reichard O, Weiland O. A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting. Scand J Gastroenterol 2008; 43: 465-472 [PMID: 18365912 DOI: 10.108 0/00365520701733806]
44. Leonardi S, Leggio T, Sciacca A, Di Gregorio F, Musumeci S. Intradermal hepatitis B vaccination in thalassaemia. Arch Dis Child 1990; 65: 527-529 [PMID: 2141464 DOI: 10.1136/adc.65.5.527]
45. Vitaliti G, Praticò AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, Leonardi S. Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 2013; 19: 838-845 [PMID: 23430309 DOI: 10.3748/wjg.v19.i6.838]
46. Kim YC, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res 2011; 1: 7-12 [PMID: 21799951]
47. Degos F, Duhamel G, Brechot C, Nalpas B, Courouce AM, Tron F, Berthelot P. Hepatitis B vaccination in chronic alcoholics. J Hepatol 1986; 2: 402-409 [PMID: 2941477 DOI: 10.1016/S0168-8278(86)80051-4]
48. Ertekin V, Tosun MS, Selimoglu MA. Is there need for a new hepatitis B vaccine schedule for children with celiac disease? Hepat Mon 2011; 11: 634-637 [PMID: 22140387 DOI: 10.5812/kowsar.1735143X.715]
49. Niiya T, Akbar SM, Yoshida O, Miyake T, Matsuura B, Murakami H, Abe M, Hiasa Y, Onji M. Impaired dendritic cell function resulting from chronic undernutrition disrupts the antigen-specific immune response in mice. J Nutr 2007; 137: 671-675 [PMID: 17311958]
50. Shakhgil'dian IV, Khukhlovich PA, Savin EA, Kuzin SN, Anan'ev VA, Sergeeva NA, Khasanova VA, Shostka GD, Vu Z, Vasil'ev AN. [Risk of infection with hepatitis B and C viruses of medical workers, patients in the hemodialysis ward, and vaccine prophylaxis of hepatitis B infection in these populations]. Vopr Virusol 1994; 39: 226-229 [PMID: 7716909]
51. European Best Practice Guidelines. Prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transpl 2002; 17: 72-87
52. Fabrizi F, Dixit V, Bunnapradist S, Martin P. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther 2006; 23: 1105-1112 [PMID: 16611270 DOI: 10.1111/j.1365-2036.2006.02877.x]
53. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007; 68: 228-234 [PMID: 17969490 DOI: 10.5414/CNP68228]
54. Centers for Disease Control and Prevention (CDC). Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb Mortal Wkly Rep 2008; 57: 875-876 [PMID: 18701878]
55. Roznovský L, Tvrdík J, Kabieszová L, Petrousová L, Orságová I, Hozáková L, Lochman I, Kloudová A, Valkovský I, Letocha P, Schwarzová S, Hladík M, Zjevíková A. [Vaccination against hepatitis B in patients with chronic renal failure-twenty years follow-up]. Vnitr Lek 2011; 57: 808-814 [PMID: 22097688]
56. Sengar DP, McLeish WA, Sutherland M, Couture RA, Rashid A. Hepatitis B antigen (HBAg) infection in a hemodialysis unit. I. HL-A8 and immune response to HBAg. Can Med Assoc J 1975; 112: 968, 971 [PMID: 1093659]
57. Sengar DP, Rashid A, Jindal SL, Christie CJ. HLA antigens in HBsAg infection. Vox Sang 1979; 36: 353-355 [PMID: 494572]
58. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol 1990; 11: 385-387 [PMID: 2290031 DOI: 10.1016/0168-8278(90)90226-H]
59. Girndt M, Sester U, Sester M, Deman E, Ulrich C, Kaul H, Köhler H. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001; 60: 2385-2391 [PMID: 11737614 DOI: 10.1046/j.1523-1755.2001.00062.x]
60. Grzegorzewska AE, Wobszal PM, Mostowska A, Jagodziński PP. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol 2012; 13: 75 [PMID: 22863216 DOI: 10.1186/1471-2369-13-75]
61. Grzegorzewska AE, Wobszal P, Jagodziński PP. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res 2012; 35: 1-8 [PMID: 21832842 DOI: 10.1159/000329932]
62. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Metaanalysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004; 20: 1053-1062 [PMID: 15569107 DOI: 10.1111/j.1365-2036.2004.02264.x]
63. Shatat HZ, Kotkat AM, Farghaly AG. Immune response to hepatitis B vaccine in haemodialysis patients. J Egypt Public Health Assoc 2000; 75: 257-275 [PMID: 17216922]
64. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984; 311: 496-501 [PMID: 6235453 DOI: 10.1056/NEJM198408233110803]
65. Brown CM, Donlon S, O'Kelly P, Casey AM, Collier C, Conlon PJ, Walshe JJ. A prospective study of hepatitis B vaccination -a comparison of responders versus nonresponders. Ren Fail 2011; 33: 276-279 [PMID: 21401350 DOI: 10.3109/08 86022X.2011.559300]
66. Fernández E, Betriu MA, Gómez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant 1996; 11: 1559-1563 [PMID: 8856211 DOI: 10.1093/oxfordjournals. ndt.a027613]
67. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996; 16: 95-97 [PMID: 8919223 DOI: 10.1159/000168977]
68. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int 2005; 67: 1136-1141 [PMID: 15698455 DOI: 10.1111/j.1523-1755.2005.00180.x]
69. Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine 2010; 28: 3773-3777 [PMID: 20371390]
70. Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 2012; 30: 931-935 [PMID: 22142584 DOI: 10.1016/j.vaccine.2011.11.086]
71. Contin C, Pitard V, Delmas Y, Pelletier N, Defrance T, Moreau JF, Merville P, Déchanet-Merville J. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology 2003; 110: 131-140 [PMID: 12941150 DOI: 10.1046/j.1365-2567.2003.01716.x]
72. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, Basile C. Hepatitis B virus infection in chronic uremia: long-term follow-up of a twostep integrated protocol of vaccination. Am J Kidney Dis 1994; 23: 537-542 [PMID: 8154489]
73. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204-1211 [PMID: 9198052 DOI: 10.1093/ndt/12.6.1204]
74. Chanchairujira T, Chantaphakul N, Thanwandee T, Ong-Ajyooth L. Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J Med Assoc Thai 2006; 89 Suppl 2: S33-S40 [PMID: 17044452]
75. Barraclough KA, Wiggins KJ, Hawley CM, van Eps CL, Mudge DW, Johnson DW, Whitby M, Carpenter S, Playford EG. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009; 54: 95-103 [PMID: 19481320]
76. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006; 24: 497-506 [PMID: 16886915 DOI: 10.1111/j.1365-2036.2006.03002.x]
77. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat 2010; 17: 879-886 [PMID: 20158604 DOI: 10.1111/j.1365-2893.2009.01249.x]
78. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virusinfected subjects. J Infect Dis 2003; 188: 571-577 [PMID: 12898445 DOI: 10.1086/377135]
79. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liverrelated mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926 [PMID: 12493258 DOI: 10.1016/S0140-6736(02)11913-1]
80. Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, Patroni A, Castelli F, Sacchi P, Filice G, Carosi G. Hepatitis B virus co-infection in human immunodeficiency virusinfected subjects. AIDS Rev 2002; 4: 27-35 [PMID: 11998781]
81. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80 [PMID: 10632283 DOI: 10.1001/jama.283.1.74]
82. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207; quiz CE1-4 [PMID: 19357635]
83. Paitoonpong L, Suankratay C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis 2008; 40: 54-58 [PMID: 17852939 DOI: 10.1080/003 65540701522975]
84. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33; quiz CE1-4 [PMID: 17159833]
85. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, Puoti M, Soriano V, Tural C. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-88 [PMID: 18257771 DOI: 10.1111/j.1468-1293.2007.00535.x]
86. European AIDS Clinical Society. Guidelines Version 6 -October 2011. Available from: URL: http://europeanaidsclinicalsociety. org/images/stories/EACSPdf/EACSGuidelinesv6.0-English.pdf
87. Geretti AM, Brook G, Cameron C, Chadwick D, Heyderman RS, MacMahon E, Pozniak A, Ramsay M, Schuhwerk M. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795-848 [PMID: 18983477 DOI: 10.1111/j.1468-1293.2008.00637.x]
88. Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, Holmberg SD. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38: 1478-1484 [PMID: 15156488 DOI: 10.1086/420740]
89. Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, Wendling MJ, Vetter D, Nicolle M, Kempf-Durepaire G, Lang JM. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161-1165 [PMID: 10649616 DOI: 10.1016/S0264-410X(99)00389-8]
90. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, Schable CA, Coleman PJ, Ostrow DN, Francis DP. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454-459 [PMID: 1825315 DOI: 10.1093/infdis/163.3.454]
91. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41: 1045-1048 [PMID: 16142673 DOI: 10.1086/433180]
92. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008; 19: 600-604 [PMID: 18725550 DOI: 10.1258/ijsa.2007.007197]
93. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a sevenyear study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008; 12: e77-e83 [PMID: 18723381 DOI: 10.1016/j.ijid.2008.05.1226]
94. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM, Mudrikova T, Brinkman K, den Hollander JG, Kroon FP, Janssen HL, van der Ende ME, de Man RA. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis 2011; 203: 984-991 [PMID: 21266513 DOI: 10.1093/infdis/jiq137]
95. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, Rimondo C, Bricolo F, Consolaro S, Trevisan M, Bosco O. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009; 27: 17-22 [PMID: 18984022 DOI: 10.1016/j.vaccine.2008.10.040]
96. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-2908 [PMID: 15780739 DOI: 10.1016/j.vaccine.2004.11.057]
97. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006; 24: 7124-7128 [PMID: 16884833 DOI: 10.1016/j.vaccine.2006.06.079]
98. Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, Silva EF, Mendonça RM, Moreira RB, Barroso PF. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012; 30: 5973-5977 [PMID: 228285 89 DOI: 10.1016/j.vaccine.2012.07.028]
99. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-245 [PMID: 19319142 DOI: 10.1038/nri2524]
100. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, Posada JG, Kardava L, O'Shea MA, Kottilil S, Chun TW, Proschan MA, Fauci AS. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010; 116: 5571-5579 [PMID: 20837780 DOI: 10.1182/blood-2010-05-285528]
101. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, Hejdeman B, Kroon FP, Lopalco L, Nilsson A, Chiodi F. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108: 1580-1587 [PMID: 16645169 DOI: 10.1182/blood-2005-11-013383]
102. Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, Bethel J, Luzuriaga K. Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 2010; 28: 3672-3678 [PMID: 20356567 DOI: 10.1016/j.vaccine.2010.03.022]
103. Goncalves L, Albarran B, Salmen S, Borges L, Fields H, Montes H, Soyano A, Diaz Y, Berrueta L. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 2004; 326: 20-28 [PMID: 15262491 DOI: 10.1016/j.virol.2004.04.042]
104. Bi X, Suzuki Y, Gatanaga H, Oka S. High frequency and proliferation of CD4+ FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol 2009; 39: 301-309 [PMID: 19089812 DOI: 10.1002/eji.200838667]
105. del Pozo Balado Mdel M, Leal M, Méndez Lagares G, Mata RC, López-Cortés LF, Viciana P, Pacheco YM. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010; 202: 362-369 [PMID: 20560766 DOI: 10.1086/653707]
106. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006; 107: 3925-3932 [PMID: 16418326]
107. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis 2012; 12: 966-976 [PMID: 23174382]
108. Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, Carrat F. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305: 1432-1440 [PMID: 21486976 DOI: 10.1001/jama.2011.351]
109. Bunupuradah T, Ananworanich J, Pancharoen C, Petoumenos K, Prasitsuebsai W, Wongngam W, Ubolyam S, Sriheara C, Lange J, Phanuphak P, Puthanakit T. Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine 2011; 29: 2962-2967 [PMID: 21329776 DOI: 10.1016/j.vaccine.2011.01.114]
110. Aziz A, Aziz S, Li DS, Murphy L, Leone N, Kennedy M, Dhillon S, Van Thiel DH. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. J Viral Hepat 2006; 13: 217-221 [PMID: 16611186 DOI: 10.1111/j.1365-2893.2005.00674.x]
111. Engler SH, Sauer PW, Golling M, Klar EA, Benz C, Stremmel W, Kallinowski B. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 2001; 13: 363-367 [PMID: 11338063 DOI: 10.1097/00042737-200104000-00010]
112. Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001; 13: 359-361 [PMID: 11338062 DOI: 10.1097/00042737-200104000-00009]
113. Dhillon S, Moore C, Li SD, Aziz A, Kakar A, Dosanjh A, Beesla A, Murphy L, Van Thiel DH. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination non-responders with chronic liver disease. Dig Dis Sci 2012; 57: 215-220 [PMID: 22160636 DOI: 10.1007/s10620-011-1996-0]
114. Leonardi S, Longo R, Cotugno M, Tardino L, Spina M, Lionetti E, La Rosa M. [Vaccination and celiac disease: results of a retrospective study]. Minerva Pediatr 2011; 63: 363-367 [PMID: 21946447]
115. Noh KW, Poland GA, Murray JA. Hepatitis B vaccine nonresponse and celiac disease. Am J Gastroenterol 2003; 98: 2289-2292 [PMID: 14572581 DOI: 10.1111/j.1572-0241.2003.07701.x]
116. Nemes E, Lefler E, Szegedi L, Kapitány A, Kovács JB, Balogh M, Szabados K, Tumpek J, Sipka S, Korponay-Szabó IR. Gluten intake interferes with the humoral immune response to recombinant hepatitis B vaccine in patients with celiac disease. Pediatrics 2008; 121: e1570-e1576 [PMID: 18519462 DOI: 10.1542/peds.2007-2446]
117. Zingone F, Morisco F, Zanetti A, Romanò L, Portella G, Capone P, Andreozzi P, Tortora R, Ciacci C. Long-term antibody persistence and immune memory to hepatitis B virus in adult celiac patients vaccinated as adolescents. Vaccine 2011; 29: 1005-1008 [PMID: 21129395 DOI: 10.1016/j.vaccine.2010.11.060]
118. Gasbarrini G, Miele L, Malandrino N, Grieco A, Addolorato G, Gasbarrini A, Cammarota G, Bonvicini F. Celiac disease in the 21st century: issues of under-and over-diagnosis. Int J Immunopathol Pharmacol 2009; 22: 1-7 [PMID: 19309546]
119. van Heel DA, West J. Recent advances in coeliac disease. Gut 2006; 55: 1037-1046 [PMID: 16766754 DOI: 10.1136/gut.2005.075119]
120. Ertem D, Gonen I, Tanidir C, Ugras M, Yildiz A, Pehlivanoʇlu E, Eksioglu-Demiralp E. The response to hepatitis B vaccine: does it differ in celiac disease? Eur J Gastroenterol Hepatol 2010; 22: 787-793 [PMID: 19584738 DOI: 10.1097/MEG.0b013e32832e9d41]
121. Leonardi S, Spina M, Spicuzza L, Rotolo N, La Rosa M. Hepatitis B vaccination failure in celiac disease: is there a need to reassess current immunization strategies? Vaccine 2009; 27: 6030-6033 [PMID: 19682619 DOI: 10.1016/j.vaccine.2009.07.099]
122. Leonardi S, Del Giudice MM, Spicuzza L, Spina M, La Rosa M. Hepatitis B vaccine administered by intradermal route in patients with celiac disease unresponsive to the intramuscular vaccination schedule: a pilot study. Am J Gastroenterol 2010; 105: 2117-2119 [PMID: 20818367 DOI: 10.1038/ajg.2010.195]
123. Leonardi S, Praticò AD, Lionetti E, Spina M, Vitaliti G, La Rosa M. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J Gastroenterol 2012; 18: 5729-5733 [PMID: 23155313 DOI: 10.3748/wjg.v18. i40.5729]
124. Pozzilli P, Arduini P, Visalli N, Sutherland J, Pezzella M, Galli C, Corradini SG, Biasio L, Gale EA, Andreani D. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 1987; 30: 817-819 [PMID: 2962892 DOI: 10.1007/BF00275749]
125. Fiçicioʇlu C, Mikla S, Midilli K, Aydin A, Cam H, Erʇin S. Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Acta Paediatr Jpn 1995; 37: 687-690 [PMID: 8775551 DOI: 10.1111/j.1442-200X.1995. tb03404.x]
126. Leonardi S, Vitaliti G, Garozzo MT, Miraglia del Giudice M, Marseglia G, La Rosa M. Hepatitis B vaccination failure in children with diabetes mellitus? The debate continues. Hum Vaccin Immunother 2012; 8: 448-452 [PMID: 22370513 DOI: 10.4161/hv.19107]
127. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, Polk BF, Syndman DR, Platt R, Crumpacker CS. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986; 105: 356-360 [PMID: 2943202 DOI: 10.7326/0003-4819-105-3-356]
128. Martinetti M, De Silvestri A, Belloni C, Pasi A, Tinelli C, Pistorio A, Salvaneschi L, Rondini G, Avanzini MA, Cuccia M. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol 2000; 97: 234-240 [PMID: 11112362 DOI: 10.1006/clim.2000.4933]
129. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, Schlossman SF, Alper CA, Yunis EJ. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991; 173: 531-538 [PMID: 1825504 DOI: 10.1084/jem.173.3.531]
130. Li Volti S, Caruso-Nicoletti M, Biazzo F, Sciacca A, Mandarà G, Mancuso M, Mollica F. Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus. Arch Dis Child 1998; 78: 54-57 [PMID: 9534677 DOI: 10.1136/adc.78.1.54]
131. Fabrizi F, Dixit V, Martin P, Messa P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther 2011; 33: 815-821 [PMID: 21281319 DOI: 10.1111/j.1365-2036.2011.04589.x]
132. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1: 377-385 [PMID: 7030902 DOI: 10.1002/hep.1840010502]
133. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O'Malley PM, Penley KA, Altman NL. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-214 [PMID: 2941687 DOI: 10.1056/NEJM198607243150401]
134. Hayashi J, Noguchi A, Nakashima K, Morofuji M, Kashiwagi S. Long term observation of the effect of intradermal hepatitis B vaccination on mentally retarded patients. Eur J Epidemiol 1991; 7: 649-653 [PMID: 1838338]
135. Heijtink RA, Breukers AA, den Hartigh G, Schepman RW, Schmitz PI, Schalm SW, Masurel N. Low dose intradermal vaccination against hepatitis B in mentally retarded patients. Vaccine 1988; 6: 59-61 [PMID: 2965462 DOI: 10.1016/0 264-410X(88)90016-3]
136. Van Damme P, Vranckx R, Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome. Vaccine 1990; 8 Suppl: S53-S55; discussion S60-S62 [PMID: 2139285]
137. Ahman L, Bäck E, Bensch K, Olcén P. Non-efficacy of lowdose intradermal vaccination against hepatitis B in Down's syndrome. Scand J Infect Dis 1993; 25: 16-23 [PMID: 8460344 DOI: 10.3109/00365549309169664]
138. Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 2013; 58: 262-264 [PMID: 23895931 DOI: 10.1016/j.jcv.2013.07.003]
139. Halliday ML, Rankin JG, Bristow NJ, Coates RA, Corey PN, Strickler AC. A randomized double-blind clinical trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine compared with a plasma-derived vaccine. Arch Intern Med 1990; 150: 1195-1200 [PMID: 2141247 DOI: 10.1001/archinte.150.6.1195]
140. Nagafuchi S, Kashiwagi S, Okada K, Anzai K, Nakamura M, Nishimura Y, Sasazuki T, Niho Y. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA 1991; 265: 2679-2683 [PMID: 1827167]
141. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, Whitby M. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002; 23: 87-90 [PMID: 11894838 DOI: 10.1086/502012]
142. Ghebrehewet S, Baxter D, Falconer M, Paver K. Intradermal recombinant hepatitis B vaccination (IDRV) for nonresponsive healthcare workers (HCWs). Hum Vaccin 2008; 4: 280-285 [PMID: 18398298 DOI: 10.4161/hv.4.4.5687]
143. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev 2005; (4): CD000100 [PMID: 16235273]
144. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 1988; 259: 365-369 [PMID: 2961895 DOI: 10.1001/jama.1988. 03720030025027]
145. Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health 1992; 46: 587-594 [PMID: 1494073 DOI: 10.1136/jech.46.6.587]
146. Avazova D, Kurbanov F, Tanaka Y, Sugiyama M, Radchenko I, Ruziev D, Musabaev E, Mizokami M. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. J Med Virol 2008; 80: 217-224 [PMID: 18098129 DOI: 10.1002/jmv.21035]
147. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355: 561-565 [PMID: 10683019 DOI: 10.1016/S0140-6736(99)07239-6]
148. Leonardi S, Leggio T, Barone P, Sciacca A, Musumeci S. Immune response of subjects at high risk of hepatitis B to a new genetically engineered hepatitis B vaccine administered in low doses by the intradermal route. Acta Paediatr Jpn 1990; 32: 361-364 [PMID: 2288216]